ACS has issued a request for applications for the Cancer Health Equity Research Centers grant.
The FY23 Defense Appropriations Act provides funding for the Peer Reviewed Cancer Research Program to support innovative, high-impact cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
The FY23 Defense Appropriations Act provides funding for the Pancreatic Cancer Research Program to support research of exceptional scientific merit and innovation with high impact that focuses on pancreatic cancer.
NCI and Cancer Research UK announced nine new research challenges aimed at tackling some of the most profound problems in cancer research. The global funding opportunity is part of the Cancer Grand Challenges program, an initiative launched by NCI and Cancer Research UK in 2020.
The FY23 Defense Appropriations Act provides funding for the Bone Marrow Failure Research Program to support innovative, high-impact bone marrow failure research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
The FY23 Defense Appropriations Act provides funding for the Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.
The FY23 Defense Appropriations Act provides funding for the Melanoma Research Program to support innovative, high-impact melanoma research.
The FY23 Defense Appropriations Act provides funding for the Ovarian Cancer Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members, and all women impacted by this disease.
The FY23 Defense Appropriations Act provides funding for the Lung Cancer Research Program to support innovative, high-impact lung cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
The Dan Lewis Foundation for Brain Regeneration Research announced the 2023 DLF Prize. The $15,000 grant will be awarded to an early career scientist in neuroscience, pharmacology, or biotechnology whose research record and future research plans align with one or more of the DLF’s current research priorities.
